Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Fiscal 2024 second quarter and six months ended October 31, 2023; unaudited. Champions is a technology-enabled oncology research organization providing pharmacology and other oncology services, alongside data, software, and drug-discovery activities. Nearly all reported revenue is oncology services revenue.
Key financial results
| Metric | Three months ended Oct. 31, 2023 | Six months ended Oct. 31, 2023 |
|---|---|---|
| Revenue | $11.6 million | $24.1 million |
| Cost of oncology services | $6.6 million | $14.3 million |
| Oncology services gross margin | 42.8% | 40.7% |
| Operating loss | $2.0 million | $4.5 million |
| Net loss | $2.1 million | $4.6 million |
| Net loss per share, basic and diluted | $0.15 | $0.34 |
| Operating cash flow | $0.6 million provided, per MD&A | $3.4 million used |
Amounts are rounded. For the six months, investing activities used $0.8 million and financing activities used $0.4 million, including $0.6 million of share repurchases partly offset by option-exercise proceeds.
Financial position and liquidity
- At October 31, 2023, cash and cash equivalents were $5.5 million, down from $10.1 million at April 30, 2023. Current assets were $14.0 million versus current liabilities of $21.0 million, including $13.0 million of deferred revenue.
- Total liabilities were $28.2 million and stockholders’ equity was only $93,000, down from $4.6 million at fiscal year-end, primarily reflecting losses and repurchases. The filing reports no off-balance-sheet debt; operating lease liabilities totaled $8.1 million, with additional finance-lease arrangements disclosed.
- Management believes cash on hand and expected operating cash flows will fund operations for at least 12 months from the filing date. It says cost-reduction strategies are available if revenue expectations are not met, but additional financing, if required, may not be available on acceptable terms.
Changes versus prior-year periods
- Quarterly revenue fell 19.0% from $14.3 million; six-month revenue fell 13.9% from $28.0 million. Management attributed the decline to increased study cancellations during fiscal 2023, which reduced bookings and convertible revenue.
- For the quarter, the company moved from a $7,000 operating profit to a $2.0 million operating loss. For six months, operating loss widened from $277,000 to $4.5 million, and net loss increased from $335,000 to $4.6 million.
- Service margins declined from 47.9% to 42.8% for the quarter and from 48.3% to 40.7% for the six-month period. Management cited lower revenue against a generally unchanged cost base.
- Six-month general and administrative expense rose 12.5% to $5.5 million, primarily due to compensation and recruiting. Research and development expense declined 3.3% to $5.3 million; approximately $2.5 million was directed to target discovery.
- Cash used in operations was $3.4 million for the first six months, versus $3.1 million provided in the prior-year period.
Outlook, risks, and notable items
- No quantified revenue, earnings, or margin guidance is provided. Management’s liquidity outlook depends partly on expected operating cash flows and revenue expectations.
- Management regularly evaluates strategic options for its drug-discovery business, potentially including a spin-out or capital raise; no specific transaction is announced.
- The company had repurchased approximately 120,300 shares for $708,000 at an average $5.73 per share under a $5.0 million authorization; approximately $4.3 million remained authorized at October 31.
- Cash deposits exceeded FDIC-insured limits by $4.3 million at period-end. The company also cites foreign-exchange exposure from international operations and estimates used in accounts receivable, revenue recognition, taxes, goodwill, and stock compensation.
- There were no legal proceedings reported and no registration-rights liquidated damages accrued. Certain tumor-model licenses carry royalties of 2%–20% under specified terms, with possible annual minimums. A $181,000 liability for uncertain tax positions remained recorded.
- The company had recognized an impairment of the Lumin software asset in fiscal 2023; no related amortization was recorded in the current six-month period. Management reported disclosure controls were effective at October 31, 2023, with no material control changes during the period.
Important facts for investors to verify
- Whether bookings and study cancellations improve enough to stabilize or restore revenue and service margins.
- Whether cash burn, working-capital needs, and the $5.5 million cash balance support management’s stated 12-month liquidity outlook.
- The drivers and sustainability of the quarterly operating cash inflow cited in MD&A, given $3.4 million of cash used in operations over six months.
- The implications of minimal stockholders’ equity, lease commitments, and continued share repurchases for liquidity and capital allocation.
- Any subsequent developments concerning strategic options, financing needs, revenue expectations, or the disclosed risk factors from the company’s latest Form 10-K.